Gwendolyn Challenger
Medical · Washington, DCNPI 1780764092
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 157 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by Novo Nordisk at 24.8% of the total. 2025 is the largest year on record at $1,501, 4.4 times the $340 reported in 2021. Among medical clinicians in DC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 157 payments — averaging $26.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$469
- Lilly USA, LLC$320
- Bayer$316
- Amgen$312
- Boehringer Ingelheim$305
- plus $1K from 20 others
What the payments were for
- Food & beverage$4,207100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 37 | $1,042 |
| AstraZeneca | 18 | $469 |
| Lilly USA, LLC | 9 | $320 |
| Bayer | 10 | $316 |
| Amgen | 12 | $312 |
| Boehringer Ingelheim | 11 | $305 |
| Teva Pharmaceuticals USA, Inc. | 7 | $207 |
| Otsuka America Pharmaceutical, Inc. | 8 | $164 |
| GSK | 5 | $146 |
| Alkermes, Inc. | 9 | $146 |
| AbbVie | 6 | $118 |
| Lundbeck LLC | 3 | $87 |
| Gilead | 3 | $82 |
| Abbott | 1 | $75 |
| Merck | 3 | $67 |
| E.r. Squibb & Sons, L.L.C. | 3 | $66 |
| Neurocrine Biosciences, Inc. | 2 | $53 |
| Dexcom, Inc. | 1 | $40 |
| Vanda Pharmaceuticals Inc. | 2 | $39 |
| Johnson & Johnson | 1 | $38 |
| Hologic Sales And Service, LLC | 1 | $22 |
| Phadia US Inc. | 1 | $22 |
| Viiv Healthcare Company | 1 | $19 |
| Pfizer | 1 | $18 |
| Medtronic | 1 | $17 |
| Neurelis, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$219
- Kerendia$122
- Austedo XR$121
- BREZTRI$119
- MOUNJARO$110
How this compares
$4,207 in reported general payments places this provider in the 90th percentile of 87 medical providers in District of Columbia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 237 | $312,467 |
| JardianceEmpagliflozin | 106 | $122,950 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $61,399 |
| EliquisApixaban | 38 | $54,242 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 12 | $47,011 |
| XareltoRivaroxaban | 37 | $40,916 |
| LinzessLinaclotide | 43 | $40,793 |
| JanuviaSitagliptin Phosphate | 33 | $40,344 |
| EntrestoSacubitril/Valsartan | 25 | $36,587 |
| MounjaroTirzepatide | 15 | $33,895 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $31,918 |
| Tresiba Flextouch U-200Insulin Degludec | 35 | $25,146 |
| MyrbetriqMirabegron | 22 | $21,741 |
| TradjentaLinagliptin | 21 | $18,592 |
| FarxigaDapagliflozin Propanediol | 14 | $11,802 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Tresiba | $1,042 | $317,920248 claims |
| Boehringer IngelheimJardiance, Tradjenta | $305 | $141,542127 claims |
| GSKTrelegy Ellipta | $146 | $61,39941 claims |
| PfizerEliquis | $18 | $54,24238 claims |
| GileadBiktarvy | $82 | $47,01112 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $469 | $43,72050 claims |
| Johnson & JohnsonXarelto | $38 | $40,91637 claims |
| AbbVieLinzess | $118 | $40,79343 claims |
| MerckJanuvia | $67 | $40,34433 claims |
| Lilly USA, LLCMounjaro | $320 | $33,89515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 87 medical providers in District of Columbia.
Other medical in Washington
- Mariella PurvisWashington$13K
- Annise Williams-NairnWashington$8K
- Teylor MartinezWashington$6K
- Hannah SagedyWashington$5K
- Amanda-Gay EdwardsWashington$4K
- Albertina DearingWashington$4K
- Susan LelacheurWashington$4K
- Melanie Scott BowlingWashington$3K
- Connor ButzWashington$3K
- Samineh AsgariWashington$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.